Navigation Links
CutisPharma Announces Strategic Collaboration with Rite Aid Corporation
Date:7/30/2008

Rite Aid to make available FIRST(R) Unit-of-Use prescription compounding

kits to its stores nationwide through Rite Aid distribution centers

WOBURN, Mass., July 30 /PRNewswire/ -- CutisPharma, Inc., an industry leader in developing products for prescription compounding, announced a partnership with Rite Aid Corporation (NYSE: RAD) that will make its innovative FIRST(R) Unit-of-Use Prescription Compounding Kits available for the approximately 27,000 pharmacists and pharmacy technicians at approximately 5,000 Rite Aid stores nationwide. Rite Aid will carry CutisPharma's FIRST(R) Unit-of-Use Prescription Compounding Kits nationwide in all its distribution centers, assuring constant availability. FIRST(R) products will allow Rite Aid the ability to offer compounding service to their customers and, for pharmacies already providing the service, increase the efficiency of their compounding offerings.

FIRST(R) Unit-of-Use Prescription-Compounding Kits are designed to provide an easy and time- saving solution for pharmacies. The pre-measured, pre- weighed components enable pharmacists to dispense the prescribed dosage accurately every time. A single NDC number assigned for the entire kit for each product greatly simplifies the third-party reimbursement process and reduces audit related adjustments. In addition, use of these kits facilitates compliance with the United States Pharmacopeia (USP) Chapter < 795 >.

"Our FIRST(R) Unit-of-Use compounding kits are user-friendly, save compounding time (by over 70%), and can be compounded by a Rite Aid pharmacist while the patient waits, increasing Rite Aid customer satisfaction and eliminating the need for an extra trip to the pharmacy," said Dr. Indu Muni, Chairman & CEO of CutisPharma.

Rite Aid Pharmacies will work with CutisPharma in notifying local physicians about the availability of compounding services at neighborhood Rite Aid stores using FIRST(R) kits.

It is estimated that approximately 30 million retail and hospital outpatient compounded prescriptions are prepared annually in the United States. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.

CutisPharma currently has nine proprietary prescription compounding kits in the market:
-- five strengths of progesterone suppository compounding kits;

-- two testosterone kits;

-- one hydrocortisone kit;

-- one Magic Mouthwash kit.

The company plans to introduce several more compounding kits in late 2008 and 2009.

About Rite Aid Corporation

Rite Aid Corporation is one of the nation's leading drugstore chains with approximately 5,000 stores in 31 states and the District of Columbia with fiscal 2008 annual sales of more than $24.3 billion. Information about Rite Aid, including corporate background and press releases, is available through the company's website at http://www.riteaid.com.

About CutisPharma, Inc.

CutisPharma, Inc., based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(R) Unit-of-Use Prescription Compounding Kits. A U.S. patent has been issued to the Company and additional patents are pending.

Contact:

James Nagle

V.P. Business Development

CutisPharma, Inc.

781-935-8141 x120

For more information please visit our website at http://www.cutispharma.com


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
2. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
3. BrainLAB Announces 510(k) FDA Clearance of Monte Carlo Dose Engine for Stereotactic Radiosurgery and Radiation Therapy
4. Align Technology Announces Second Quarter Fiscal 2008 Results
5. Monogram Announces 2008 Second Quarter Financial Results
6. Webcast Alert: Medial Saude S/A Announces Second Quarter 2008 Earnings Conference Call Webcast
7. The Quantum Group Announces Exclusive Screening of New PWeR(TM) System
8. Burgess Announces Expanded Software Partnership With Health Net
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Fast Radios Announces Publication of Two Way Radio Guide for Commercial Customers
11. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... Journal of Oral Implantology – Tooth loss ... overall dental health, including complications with speech, eating, and overcompensation of mouth due to ... lost teeth. As the number of tooth replacements increase, it is imperative to design ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president and CEO ... Enterprising Women magazine as one of its 2017 Enterprising Women of the Year, ... have demonstrated that they have fast-growth businesses, mentor or actively support other women ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you ... to get nutrients from SUPERFOODS! , RawTrition is taking nutrients to the ... level because the body recognizes its raw form (unlike the synthetically made options that ...
(Date:4/26/2017)... FL (PRWEB) , ... April 26, 2017 , ... ... and human performance, is proud to announce that it has received 510(k) clearance ... technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary ...
(Date:4/25/2017)... ... 25, 2017 , ... Coalition Duchenne, a ... muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on positive ... trial in Duchenne announced today. , Coalition Duchenne funded studies carried out ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology: